Eyepic is proud to offer the only FDA-approved, cross-linking procedure for treating keratoconus, iLink™. Backed by 20 years of science, iLink™ is a proprietary, minimally invasive procedure that slows or sometimes even halts progressive keratoconus to help preserve vision. Why is this important? If left untreated, one in five people diagnosed with progressive keratoconus may require a corneal transplant. Untreated keratoconus can also lead to higher risk of vision loss and a less than ideal vision quality of life. It is important to also note that more than half of the people who undergo a corneal transplant may need multiple transplants within 20 years thereafter.
The good news is this FDA-approved, cross-linking procedure works to keep that from being your future. Over 400,000 cross-linking procedures have been performed worldwide with the iLink™ equipment, and we hope to help those with progressive keratoconus by adding to that number. As with offering any new service, we expect you to have some questions. We hope these will help, and if you have a question not listed below, feel free to give us a call.
Who backs the iLink™ procedure?
Not only is iLink™ the only FDA-approved, therapeutic treatment for this ocular disease, both the American Academy of Ophthalmology as well as the Cornea Society recommend cross-linking for the treatment of progressive keratoconus, making it the new standard of care.
What’s so special about this procedure?
First, it can reduce or delay the need for more invasive procedures down the road. Second, it can offer you peace of mind knowing this one-time procedure is widely covered by commercial medical insurance (to see if it is covered under your insurance, we recommend you reach out to verify). Third, keratoconus is serious and can lead to vision loss, which is commonly associated with anxiety, depression, and ability to remain independent. iLink™’s goal is to prevent that from happening.
We’re here to be there every step of the way on your keratoconus journey. Schedule an appointment to discuss your options today, by clicking here.
IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision. These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to http://www.livingwithkeratoconus.com to obtain the FDA-approved product labeling. You are encouraged to report all side effects to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.